Physician profile
Timothy E Hohman
NPI 1063768810
$3,424.22
in general payments reported to CMS, 2019-2025
26 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $2,062 · 2022: $750 · 2023: $498 · 2024: $114.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $612.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $612.11 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,221.12 | 2021-2024 | |
| Pfizer INC. | $312.24 | 2021-2022 | |
| Amgen INC. | $308.57 | 2021-2022 | |
| Novo Nordisk INC | $184.82 | 2021-2022 | |
| Biohaven Pharmaceuticals, INC. | $157.91 | 2021 | |
| Sunovion Pharmaceuticals INC. | $124.27 | 2021 | |
| Daiichi Sankyo INC. | $123.04 | 2021-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $113.45 | 2021-2022 | |
| Lilly USA, LLC | $112.77 | 2021-2022 | |
| Amarin Pharma, INC. | $80.50 | 2021 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $66.12 | 2021-2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $63.93 | 2021-2022 | |
| Ucb, INC. | $61.42 | 2021 | |
| Currax Pharmaceuticals LLC | $57.05 | 2021 | |
| Esperion Therapeutics, INC. | $56.39 | 2021 |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Teva Pharmaceuticals USA, INC. | $55.29 | 2021-2022 | |
| Astrazeneca Pharmaceuticals LP | $54.67 | 2021 | |
| Abbott Laboratories | $48.67 | 2021-2022 | |
| E.R. Squibb & Sons, L.L.C. | $42.47 | 2021 | |
| Astellas Pharma US INC | $39.34 | 2021 | |
| Glaxosmithkline, LLC. | $38.67 | 2021 | |
| Xeris Pharmaceuticals, INC. | $31.73 | 2021 | |
| Biohaven Pharmaceutical Holding Company LTD. | $31.19 | 2022 | |
| Genentech USA, INC. | $15.01 | 2021 | |
| Redhill Biopharma INC. | $12.34 | 2022 | |
| Nestle Healthcare Nutrition INC. | $11.24 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Timothy Hohman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.